Trial Profile

A Phase 3 trial of SB 9225 (inarigivir + tenofovir disoproxil fumarate)

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inarigivir-soproxil/tenofovir-disoproxil-fumarate (Primary)
Indications Hepatitis B
Focus Therapeutic Use

Most Recent Events

11 Mar 2019 According to a Spring Bank Pharmaceuticals media release, based on the results of the company's CATALYST Phase 2b inarigivir trials and the ongoing Gilead co-administration studies, the company could initiate this Phase 3 program for SB 9225 in 2020.
22 Mar 2018 New trial record
20 Mar 2018 According to a Spring Bank Pharmaceuticals media release, this trial is anticipated to initiate in 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com